Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast CancerN. Lynn Henry, Anna Maria Storniolo, Faouzi Azzouz et al.|Journal of Clinical Oncology|2012Cited by 391
Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer PatientsSilvana Borges, Lang Li, Zeruesenay Desta et al.|The Journal of Clinical Pharmacology|2010Cited by 128
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohortN. Lynn Henry, Vered Stearns, James M. Rae et al.|Breast Cancer Research and Treatment|2009Cited by 74
Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapyJulie L. Otte, Janet S. Carpenter, David A. Flockhart et al.|Menopause The Journal of The North American Menopause Society|2009Cited by 27
A SNP in Steroid Receptor Coactivator-1 Disrupts a GSK3β Phosphorylation Site and Is Associated with Altered Tamoxifen Response in BoneRyan J. Hartmaier, Steffi Oesterreich, Andreas S. Richter et al.|Molecular Endocrinology|2011Cited by 20